| Reference: | 參考文獻
1. Ansoff, I.: Strategies for Diversification, Harvard Business Review, Vol. 35 Issue 5,Sep-Oct 1957, pp. 113-124
2. Alexion, (http://news.alexionpharma.com/press-release/company-news/alexion-completes-acquisition-synageva)
3. Bauer et.al., (2014) "Antecedents of m&a success: the role of strategic complementarity, cultural fit, and degree and speed of integration. ", Strategic Management Journal, 35: 269-291
4. Bloomberg system (NCCU library)
5. Carmine Ornaghi, (2006) "Mergers and Innovation: the Case of the Pharmaceutical Industry. ", University of Southampton (http://citesee-rx.ist.psu.edu/viewdoc/download?doi=10.1.1.627.467&rep=rep1&type=pdf)
6. Celgene (http://ir.celgene.com/releasedetail.cfm?releaseid=922090)
7. Florian Szücs, (2013) "M&A and R&D: Asymmetric E↵ects on Acquirers and Targets? ", Deutsches Institut für Wirtschaftsforschung
8. Fortune, (2015) (http://fortune.com/2015/07/15/pharma-ma-boom-rolls-on-now-celgenes-buying-receptos/)
9. IMS PharmaDeals Review, (2015, 2016)
10. Jeffrey Jung, (2002) "Creating breakthrough innovation during a pharmac-eutical merger or acquisition.”, IBM Institute for Business Value manuscript
11. Mehmet Demirbag, Chang‐Keong Ng, Ekrem Tatoglu, (2007) "Performance of Mergers and Acquisitions in the Pharmaceutical Industry: A Comparative Perspective", Multinational Business Review, Vol. 15 Issue: 2, pp.41-62
12. Mahmud Hassan, Dilip K. Patro, Howard Tuckman, Xiaoli Wang, (2007) "Do mergers and acquisitions create shareholder wealth in the pharmaceutical industry?", International Journal of Pharmaceutical and Healthcare Marketing, Vol. 1 Issue: 1, pp.58-78
13. Marc Kirchhoff and Dirk Schiereck, (2011) "Determinants of M&A Success in the Pharmaceutical and Biotechnological Industry", IUP Journal of Business Strategy, Vol. VIII, No. 1
14. Statista (https://www.statista.com/statistics/272181/world-pharmaceutical-sales-by-region/)
15. Statista (https://www.statista.com/statistics/265085/research-and-development-expenditure-us-pharmaceutical-industry/)
16. Statista (https://www.statista.com/statistics/407976/projected-revenues-of-top-us-pharmaceutical-patent-expiries/)
17. Seeking Alpha, (2015), (https://seekingalpha.com/article/3342275-an-assessment-of-celgenes-deal-for-receptos)
18. StreetInsider.com,(https://www.streetinsider.com/Corporate+News/AbbVie+%28ABBV%29+Announces+Completion+of+Pharmacyclics+Acquisition/10594347.html)
19. 勤業眾信-生技醫療專欄 (https://www2.deloitte.com/tw/tc/pages/life-sciences-and-healthcare/articles/newsletter-11-16.html)
20. 劉崇明，陳丹, (2008)「關於企業併購支付方式合理選擇的因素與對策」,華北電力大學工商管理學院月刊
21. 李冀東 (2012)，芻議企業併購融資中國鄉鎮企業會計
22. 丁玉芳，鄧小軍 (2009)，高級財務管理：理論與實務，經濟管理出版社
23. 徐晶 (2004)，我國企業併購融資問題分析，商業研究
24. 吳松齡 (2004)，企業談判：理論與實務，滄海書局
25. 許勁上 (2016)，併購中的溝通與談判技巧，互聯網金融投資
26. 朱濤 (2006)，上市公司併購的長期和短期股價表現，當代經濟學
27. 廖俊杰、陳家妤 (2009)，賣貴了還是買對了？主併者併購溢價與長短期股票報酬的非線性關係，中華管理評論國際學報，第12卷第二期
28. 王祝三、周德瑋與陳弘榮 (2006)，企業併購支付方式決定因素與股價反應之探討，證券市場發展季刊
29. 陳安琳、湯惠雯與許銘峻 (2000)，企業併購對主併公司股東財富的影響，Asia Pacific Management Review
30. 網站：https://kknews.cc/zh-tw/science/3xx6la.html |
